PB2126: R-CPOP AS FIRST LINE TREATMENT FOR DLBCL PATIENTS WITH SIGNIFICANT REDUCED LVEF OR HIGH RISK OF ANTHRACYCLINE INDUCED CARDIOTOXICITY - K. Lorenz; T. Strüßmann; M. Trepel; G. Illerhaus; H. Pelz; C. Scholz; J. Duyster; R. Marks (HemaSphere, 2022)